% | $
Quotes you view appear here for quick access.

Standard Pacific Corp. Message Board

tazamatic2002 73 posts  |  Last Activity: Feb 9, 2016 2:09 PM Member since: Jun 1, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • tazamatic2002 tazamatic2002 Feb 9, 2016 2:09 PM Flag

    I will take JNJ's estimate of on market by end of 2017

  • they are getting slammed today

  • Reply to


    by gabe8525 Feb 8, 2016 11:53 AM
    tazamatic2002 tazamatic2002 Feb 8, 2016 11:56 AM Flag

    there is no up tic rule anymore

  • tazamatic2002 tazamatic2002 Feb 8, 2016 10:10 AM Flag

    Ford is building a plant in Mexico and even if Trump was President he could do Nada to stop it. wegbox and you do not back the first ever Jewish man running for President. A historic moment and no one talks about it.

  • Reply to

    Xoma 358

    by tazamatic2002 Feb 4, 2016 12:58 PM
    tazamatic2002 tazamatic2002 Feb 8, 2016 9:53 AM Flag

    Clinical Trials dot gov the trial ends with final collection 2 months prior to date I gave and with small numbers in the trial data should release in 2 months after trial final data collection.

  • tazamatic2002 by tazamatic2002 Feb 4, 2016 12:58 PM Flag

    London trial site open should get results by July or September this year

  • Reply to

    GERN Plants?

    by blackmarango Feb 1, 2016 1:03 PM
    tazamatic2002 tazamatic2002 Feb 1, 2016 4:27 PM Flag

    2010 Shareholder meeting at the old Lab now AST Dr Kelsey had mentioned that some do read but none would dare post the termination issue and SEC disclosure compliance.

  • Reply to

    GERN Plants?

    by blackmarango Feb 1, 2016 1:03 PM
    tazamatic2002 tazamatic2002 Feb 1, 2016 3:42 PM Flag

    From shareholders meeting in the past posting on stock message boards constitutes terms for termination.

  • Reply to

    MDS is in phase III ?

    by donquixote2035 Jan 29, 2016 2:19 PM
    tazamatic2002 tazamatic2002 Jan 29, 2016 4:46 PM Flag

    It all depends on how long it takes JNJ to reach the 2 arm patient numbers and how long it takes them to analyze the numbers then shift to a single arm trial. My guess is by June but the latest would be Ash. We may get a shift from Phase 2 to Phase 3 and an opt in by JNJ first. By the way one would expect about 30% to 40% drop out rate on the MF trial using Scarlett's 66% stable disease figures from Dr Tefferi's trial data.

  • Reply to

    MDS is in phase III ?

    by donquixote2035 Jan 29, 2016 2:19 PM
    tazamatic2002 tazamatic2002 Jan 29, 2016 4:14 PM Flag

    I wanted to thank you for the updates on the MF support group postings you have been doing very good parsing of information and questioning. From the answers and responses to your questioning there are several things that are evident. First the person posting to the board is an RN working at an NY surgical clinic and as a home health care nurse, and from her most recent post asking about side effects to Jakafi it makes me wonder if her mom was ever on Jakafi before. The fact that this is most likely a New York patient and New York came on line in mid October for recruiting and screening takes about 1 to 2 months makes me wonder if the 4 doses is accurate.

  • Reply to

    A relative of a patient in Imetelstat trial

    by ligas3 Jan 27, 2016 3:29 PM
    tazamatic2002 tazamatic2002 Jan 29, 2016 3:27 AM Flag

    my only concern from reading the post is the daughter is a nurse yet her mom was never on Jakafi until you pointed out it was a requirement of entering the trial to have failed on Jakafi. My brothers wife is a now retired nurse and she knows all 16 meds my mom takes. Nurses tend to keep track of what their loved ones are taking in treatments.

  • Reply to

    What are Geroniacs looking at?

    by jacosa Jan 27, 2016 7:42 PM
    tazamatic2002 tazamatic2002 Jan 28, 2016 11:54 AM Flag

    The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.

    Koziel JE1, Herbert BS.

    Author information


    Cancer stem cells (CSCs) are thought to be responsible for tumor progression, metastasis, and recurrence. HER2 overexpression is associated with increased CSCs, which may explain the aggressive phenotype and increased likelihood of recurrence for HER2(+) breast cancers. Telomerase is reactivated in tumor cells, including CSCs, but has limited activity in normal tissues, providing potential for telomerase inhibition in anti-cancer therapy. The purpose of this study was to investigate the effects of a telomerase antagonistic oligonucleotide, imetelstat (GRN163L), on CSC and non-CSC populations of HER2(+) breast cancer cell lines. The effects of imetelstat on CSC populations of HER2(+) breast cancer cells were measured by ALDH activity and CD44/24 expression by flow cytometry as well as mammosphere assays for functionality. Combination studies in vitro and in vivo were utilized to test for synergism between imetelstat and trastuzumab. Imetelstat inhibited telomerase activity in both subpopulations. Moreover, imetelstat alone and in combination with trastuzumab reduced the CSC fraction and inhibited CSC functional ability, as shown by decreased mammosphere counts and invasive potential. Tumor growth rate was slower in combination-treated mice compared to either drug alone. Additionally, there was a trend toward decreased CSC marker expression in imetelstat-treated xenograft cells compared to vehicle control. Furthermore, the observed decrease in CSC marker expression occurred prior to and after telomere shortening, suggesting that imetelstat acts on the CSC subpopulation in telomere length-dependent and -independent mechanisms. Our study suggests addition of imetelstat to trastuzumab may enhance the effects of HER2 inhibition therapy, especially in the CSC population.

  • Reply to


    by ptcamd Jan 27, 2016 6:58 AM
    tazamatic2002 tazamatic2002 Jan 27, 2016 12:22 PM Flag


  • Reply to


    by ptcamd Jan 27, 2016 6:58 AM
    tazamatic2002 tazamatic2002 Jan 27, 2016 11:57 AM Flag

    last update was MDS Jan 20

  • Reply to

    MDS trial ramp up

    by tazamatic2002 Jan 25, 2016 11:10 PM
    tazamatic2002 tazamatic2002 Jan 25, 2016 11:20 PM Flag

    Antwerpen, Belgium
    Brasschaat, Belgium
    Gent, Belgium
    Kortrijk, Belgium
    Tours, France
    Amsterdam, Netherlands
    Groningen, Netherlands
    St. Louis, Missouri, United States
    Baltimore, Maryland, United States
    Bethesda, Maryland, United States
    Louisville, Kentucky, United States

  • tazamatic2002 by tazamatic2002 Jan 25, 2016 11:10 PM Flag

    is going faster than MF trial 11 sites are now recruiting

  • tazamatic2002 by tazamatic2002 Jan 19, 2016 5:08 PM Flag

    everytime he floats a false rumor it is time to buy he has never been right in the rumor department.

  • MF sites in US recruiting
    Site #60521 Baltimore MD 21229-5201
    Site #60568 Duarte CA 91010 369
    Site #60565 La Jolla CA 92093 464
    Site #60547 Seattle WA 98109 618
    Site #60571 Rochester MN 55902 1534
    Site #60537 St. Louis MO 63110 1671
    Site #60538 Louisville KY 40202 1915
    Site #61772 Greenville SC 29607 2158
    Site #60536 Baltimore MD 21201 2378
    Site #60566 Philadelphia PA 19104 2443
    Site #60528 New York NY 10029 2491
    Site #60532 Bronx NY 10467 2495

    MDS sites in the US recruiting
    Site #71197 Baltimore MD 21229-5201
    Site #71232 St. Louis MO 63110 1671
    Site #71224 Louisville KY 40207 1915
    Site #71195 Bethesda MD 20817 2357

  • but growing at the same amount means the growth rate decreases because the base is higher. here is the example if China grows 7.1 every year for 3 years here is what happens to the growth rate. year 1 the growth rate is 7.1/100 = 7.1% year 2 it is 7.1/107.1= 6.6% year 3 is 7.1/113.7=6.24%.

  • Reply to

    Yahoo Insider Transactions

    by beavertail_splash Jan 18, 2016 8:48 AM
    tazamatic2002 tazamatic2002 Jan 18, 2016 11:39 AM Flag

    NASDAQ Institutional ownership

    Institutional Holdings 45.15%

    Total Number of Holders 147
    Total Shares Held 71,434,048
    Total Value of Holdings $238,589,720
    Net Activity (680,869)
    calculated change in percentage of ownership 0.945% that is slightly less than a 1% change in amount owned by institutions. There were 22 that sold out and 14 New positions established. Some increased positions while others decreased.
    Yahoo is always way off on the numbers